a public good project by the
Synthesis
Company
of California

© 2026

Bivalirudin versus heparin and provisional GP IIb/IIIa inhibitors in patients treated for ST‐segment elevation myocardial infarctions: Comparison of outcomes in a “real‐world” setting | doi.page

0 citations0 references

Google Scholar doi.org

Bivalirudin versus heparin and provisional GP IIb/IIIa inhibitors in patients treated for ST‐segment elevation myocardial infarctions: Comparison of outcomes in a “real‐world” setting

Journal of Interventional Cardiology·2017·Vol. 30(4), pp. 301–308

Citations Over Time

Andreas Fach, Tina Backhaus, Johannes Schmucker, Robert Zabrocki, Daniela Garstka, J. Stehmeier, Eduard Fiehn, Rainer Hambrecht, Harm Wienbergen

Abstract

In this "real-world" cohort of patients with STEMI bivalirudin compared to heparin and GPIs was associated with less bleedings and no significant differences in stent thromboses, reinfarctions, and mortality during hospital and long-term course.

Citations Over Time

Abstract

Related Papers